S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in
ASX:IMC

Immuron Limited (IMC.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.09
MA: A$0.08
A$0.09
52-Week Range N/A
Volume175,856 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.

MarketRank

Overall MarketRank

0.54 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 3 9824 5254
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.52 million
Book ValueA$0.03 per share

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Receive IMC News and Ratings via Email

Sign-up to receive the latest news and ratings for IMC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Immuron Limited (IMC.AX) (ASX:IMC) Frequently Asked Questions

What stocks does MarketBeat like better than Immuron Limited (IMC.AX)?

Wall Street analysts have given Immuron Limited (IMC.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Immuron Limited (IMC.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Immuron Limited (IMC.AX)'s key competitors?

Who are Immuron Limited (IMC.AX)'s key executives?

Immuron Limited (IMC.AX)'s management team includes the following people:
  • Dr. Jerry Kanellos Ph.D., CEO & COO (Age 59, Pay $244.54k)
  • Mr. Peter Anastasiou, Exec. Vice Chairman (Age 60, Pay $37.5k)
  • Mr. Phillip Allen Hains, CFO & Company Sec. (Age 61)
  • Mr. David Lyon, Head of Marketing

What is Immuron Limited (IMC.AX)'s stock symbol?

Immuron Limited (IMC.AX) trades on the ASX under the ticker symbol "IMC."

How big of a company is Immuron Limited (IMC.AX)?

Immuron Limited (IMC.AX) has a market capitalization of $0.00 and generates $2.52 million in revenue each year.

What is Immuron Limited (IMC.AX)'s official website?

The official website for Immuron Limited (IMC.AX) is www.immuron.com.au.

How can I contact Immuron Limited (IMC.AX)?

The company can be reached via phone at 61 3 9824 5254.

This page was last updated on 1/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.